1

Georgia O’Keeffe Inspirational at the Peabody Essex

Still thinking about the fabulous Georgia O’Keeffe show I saw last Sunday at the Peabody Essex Museum, in Salem, MA. “Georgia O’Keeffe: Art, Image, Style,”  is a retrospective going back to O’Keeffe’s high school years. It continues through her experiences in Chicago, Texas, New York City, Lake George, New Mexico and beyond her lifetime, to the present day.

 

 

The exhibit  features not only her art work through those years, but also year-book entries, photos of and by O’Keeffe, video of a conversation in which she says she was lucky that her work coincided with her time and was liked but that her paintings might have been better if she’d remained unknown.

Central to the show is the distinctive clothing she designed and wore–presented in relation to her paintings.

 

 

 

 

The show includes video from a 2018 fashion show in which models prance on a runway. wearing styles like those originated by OKeefe.(immediately below)

My friend E remarked on O’Keeffe as a feminist force. But while O’Keeffe was a ground breaker in the art world and is sometimes referred to as “the mother of abstract art,” a PEM commentary points out that she insisted throughout her career that she did not want to be considered a female artist…but simply an artist.

I did wonder what would have happened if famed New York City photographer Alfred Stieglitz, 30 years her senior, had not seen her work when she was a young artist and championed it–and her; if she had not moved to New York and married him; if he had not taken and shown photograph after photograph of her; if she had not had the safety and freedom afforded by Stieglitz and his family wealth in NY and Lake George. But an example of the early commercial artwork (left), on which she embarked to supplement her Texas teaching salary, makes me certain she would have become renowned on her own.

 

 

While I love most of O’Keeffe’s  paintings, I’m less enamoured of her fashion, which the show presents as an element of her artwork.  In my view, it seems to have become more traditionally masculine–with chunky-looking  black suits ordered from a men’s clothier in Hong Kong– as she moved on in life.(Or, as women’s societal roles changed?) 

 

 

 

 

 

 

 

 

 

 

 

I’ve  seen quite a few O’Keeffe shows over the years..several in New York, and one in Glens Falls, NY, near Lake George– but this is the first I’ve seen that incorporates and integrates so many aspects of her life.

I would have liked to have been told a bit more about O’Keeffe’s childhood and family and about her relationship with Stieglitz, but then, there’s Wikipedia for that. All in all, I found the exhibit of an artist who worked well into her 90s enriching and inspirational.

 

Should also mention the wonderful docent and ceramic artist/jewelry maker who told me that the unlabelled photos were taken by O’Keefe and encouraged me and other visitors to share our comments and photos on Instagram.  Also, btw, the PEM  cafeteria serves the richest, thickest hot chocolate I’ve ever tasted.

Georgia O’Keefe, Art, Image, Style will be at the Peabody Essex Museum, Salem, MA, Dec. 1-April 1, 2018. 

–Anita Harris
Anita M. Harris is a writer, photographer and communications consultant  basedin Cambridge, MA. She is the author of Ithaca Diaries, Coming of Age in the 1960s, and Broken Patterns: Professional Women and the Quest for a New Feminine Identity.

New Cambridge Observer is a publication of the Harris Communications Group, a PR and content marketing firm based in Kendall Square. :




Don’t miss Nov. 12 deadline to enter $22K biotech award competition; Nov. 19 event

Our colleague Seth TaylorMedical_Laboratory_Scientist_US_NIH asked us to let you know that BioTechTuesday will be holding a $22K Life Science Innovation Competition and Pitch event on November 19; deadline to enter the competition is Tuesday, Nov. 12.

Here’s the scoop:

BiotechTuesday, a networking organization for life science professionals, will hold an innovation competition at which major pharmaceutical and biotechnology companies will award $22K in funds and in-kind services.   The winners will be life-science startups and researchers judged to have the most innovative ideas and laboratory products.

The event will take place at District Hall, a new event space at 75 Northern Avenue in the Boston Seaport District, from 6-9, on Tuesday, November 19.

Awards include:

  • Financial and in-kind prizes for the most promising startup concepts and early stage ventures. Innovators can submit their concept or venture online for consideration by November 12, 2013. The BiotechTuesday community will then vote online—contributing to the selection of five finalists who will pitch their concepts at the event. At the event, competition judges from Novartis, EMD Serono, Pharmatek and others, will choose the winners.  CLICK HERE TO ENTER[http://goo.gl/gBhiaq]
  • Recognition for the most innovative recently-launched products or services. Companies can submit recently launched products or services online for consideration, by November 12, 2013.  Finalists will present their pitches one-on-one to attendees and judges at the event.  CLICK HERE TO ENTER [http://goo.gl/03Q7pG]

“This competition event is unique in that it relies on a true community from a top life-science super cluster to select and validate some of the most exciting new approaches in the field,” said Seth Taylor, BiotechTuesday co-founder and host. “It provides a tremendous opportunity for the community to engage with innovators launching the hot companies of the future, and products that may impact their work today.”

Peter Parker, co-founder and director of programming for LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences startups, said: “We share in Biotech Tuesday’s mission to advance innovation in the life-sciences community. We are pleased to offer one month’s free membership and a bench space in LabCentral’s co-working lab and office facility ($4,000 value). LabCentral provides fully functional lab space, permits, waste handling, plus all reasonably common lab equipment for bioresearch. Access to conference rooms and event space,  kitchens, etc. is also included, as is participation in programming specific to the interests of life-sciences startups.”

In the words of Charles Wilson, Vice President and Head of Business at Novartis Institutes for Biomedical Research, Inc:  “We believe that the time and expertise of large companies can be of great value to startups.  For this reason, we have committed to offering resources and analysis to help a winning company reach investors and commercialize their therapeutics.”

Timothy Scott, President and Co-Founder, Pharmatek Inc., a contract research organization offering $3000 in reagents to the winning team, said:  “We are committed to supporting innovation with our products and services, and through our Pharmatek University educational programs,”

Event attendance is open to the public. Click here to register [http://goo.gl/fRUh1J].

BioTechTuesday is a networking organization offering monthly events and an online community for life science professionals.  Founded in 2002 in the Boston area, BiotechTuesday now has thousands of members. 

Contact: Seth Taylor 617-615-6152    staylor@biotechtuesday.com   Twitter: #pitchbio

New Cambridge Observer is a publication of the Harris Communications Group, an award-winning PR and market development firm specializing in strategic communication, media relations, social and digital media for health care, life science, biotech, tech and energy.  

 




Cambridge’s Luke Farrar Kickstarts fundraising for Aussie Claustral Canyon 3-D Film

Claustral Canyonc_largeFront cover of National Geographic

 

 

 

 

 

 

 

 

With 17 days to go, and at 37% of his target, 3-d filmmaker Luke Farrar says things are going quite well for his Kickstarter campaign to fund an amazing filmmaking project–using a novel, 3-D camera–to bring a beautiful Australian  canyon to your computer Screen.

Luke says Claustral Canyon is one of the world’s most ancient and beautiful slot canyons. Fifty million years old, it is ten times older than the Grand Canyon. There is no record of the Aboriginals ever having been there, which only adds to the mystery of the place. The canyon was only explored for the first time in the 1960s.

Here’s a link to Luke’s Kickstarter page, which includes a video explanation and demonstration of the project. Luke is based at the CIC, where I work; great if you could help him out with a few bucks.

Journey To A Lost Canyon .

–Anita Harris
New Cambridge Observer is a publication of the Harris Communications Group, an award-winning PR and digital marketing firm working with health, science, technology, energy and the environmental clients, worldwide. 

 

 

 




Bid on lunch with pharma exec; benefit Water-Aid, developing world

Want  to  lunch one-on-one with a senior exec from a major pharma company and help people in the developing world at the same time?

UK/US Life science consulting firm Alacrita,  based in the Cambridge Innovation Center, has launched a benefit auction in which you can bid for a two-hour, one-to-one lunch with senior executives from the pharmaceutical industry who have donated their time to the appeal.

According to Alacrita Partner Rob Johnson,   the appeal aims to raise money for WaterAid, an international non-profit organization that  transforms the lives of people in the world’s poorest countries by improving access to safe water and sanitation.

Bidding opened Monday 3rd December and closes on Thursday 13th December on 5pm EST/10pm GMT.

In order to bid,  click on a name, below. You will be redirected to eBay for bidding.

  • Heather Bell, Head of Corporate Strategy and Shaun Grady, Head of Business Development at AstraZeneca (one lunch)
  • Moncef Slaoui, Chairman, Research & Development at GlaxoSmithKline
  • Douglas Giordano, Senior Vice President, Worldwide Business Development at Pfizer
  • Susan Silbermann, President and General Manager, Vaccines, Specialty Care Business Unit and Polly Murphy Vice President, Specialty Care Business Unit Business Development at Pfizer (one lunch)
  • Graham Brazier, Vice President, Business Development, Strategic Transactions Group at Bristol-Myers Squibb
  • Pamela Demain, Executive Director, Corporate Licensing at Merck
  • Susan Jane Herbert, Executive Vice President and Head of Global Business Development and Strategy and Annalisa Jenkins, Executive Vice President and Head of Global Drug Development & Medical and Belen Garijo, Executive Vice President and Chief Operating Officer at Merck Serono (one lunch)

Bidding  will be open until 13th December, 5pm EST/10pm GMT.

Johnson said: “We are thrilled to launch this year’s seasonal appeal to raise funds for WaterAid. 783 million people, or one in ten of the world’s population, live without access to safe water and last year WaterAid reached 1.6 million people with water and 1.9 million people with sanitation in 27 countries. ”

David Winder, CEO of WaterAid, America added: “We are delighted that Alacrita has chosen to  donate the proceeds of their charity auction to  WaterAid.  Every day, 2,000 children die from water-related diseases that could easily be prevented.  The funds raised will help us reach more of the world’s poorest people with safe, clean water and sanitation.  These vital basic services are essential for saving  lives, improving health and reducing poverty in the world’s poorest countries.”

 

–Anita M. Harris
New Cambridge Observer is a publication of the Harris Communications Group,  an award-winning PR/content marketing and social media firm specializing in health, science, technology and energy.




Downturn + changing VC industry = funding challenges for startups

For entrepreneurs seeking venture capital funding, there’s good news—and there’s bad news. The good news is that  it’s easier now than at any time in the last ten years to get relatively small amounts of seed money. The bad news is that it’s harder to obtain “A Round” or additional series funding after that.

That was the consensus of  three Boston area venture capitalists who spoke at the Cambridge Innovation Center on  Wednesday, May 2.  Moderator Ben Hron of  law firm McCarter -English, which sponsored the event, asked the VCs  how the 2008 economic downturn  has impacted the VC industry;  where things stand now,  and what they foresee for the future.

Impact of the recession
A changing industry
Jo Tango, founder and partner of Kepha Partners, which invests in early stage companies, said that for many VC firms, this is a period of innovation. “We call it VC 2.0,”  he quipped to the audience of  entrepreneurs.  The VC industry, which started in about 1980, used to be dominated by approximately 20 major firms; today, there are more smaller, more specialized VC firms, he said.

David Beisel, co-founder and partner of  NextView Ventures, a dedicated seed-stage venture capital firm focused on Internet startups, said that the downturn has “facilitated a  maturation process,” which he likened to what happened in the beer industry in the 1990s.

That is, “You had to be either one of the biggest, like Anheuser-Busch—or a microbrewery.” Mid-size companies like Genesee fell by the wayside.

Likewise,  today,  he said, “VC firms are no longer trying to be all things to all entrepreneurs; they’re taking a dedicated approach.  Recently, four or five firms raised more than $1B but mid-sized firms are struggling.”

CA Webb, Executive Director of the New England Venture Capital Association, said that considering this a time of “introspection and innovation” is “optimistic…The reality is that the industry is taking a hard look at itself. Some say that the ‘sky is falling,’ because there’s less money being invested; this means that some firms will shut down. Those that succeed will need to articulate clearly just what they are willing to offer and to whom.”

Tango pointed out that “Innovation [in the VC industry] creates a challenge for entrepreneurs because VC firms are “all over the map,” and “it’s difficult to know which one is right for [a particular startup]. It’s easier now to get seed money–but terms are often more difficult to distinguish.”

 

Current trends
In asking the panelists for their views on the current venture funding situation, Hron shared Q1 2012 statistics showing  a large number of deals but a drop in total funding compared with previous quarters– in indicating fewer “megadeals.”  “Should entrepreneurs should be optimistic because of the number of deals or pessimistic about the size of the deals?” he asked.

Fewer large deals
Tango responded that one reason for the decline in large deals has to do with the number of deals VCs have previously closed.  In the current economic climate, he explained, it’s difficult raise a stream of money. In a recent study of five VC Web sites, his firm found that many VCs are already sitting on the boards of 10-17 companies in which they have invested. “If you’re fundraising…if you’re already on 15 boards, you need to spend your time fund raising,” not sitting on additional boards.

Smaller investments
Beisel described what he called a longer term trend:  in some sectors, especially digital media, companies don’t need to raise as much money for initial funding as in other sectors–so at earlier stages, the venture community is reacting by not writing $5M checks but rather $1M or .5 M.

In Webb’s view, “seeding is now like the old Series A funding: there is a lot of seed money to go around but Series A is now looking like the old series C “(IE–difficult to come by).

Follow-on funding can be problematic.
Tango agreed –describing a firm that backed 20 companies with seed money but told him it will provide only 2 % of those with Series A funding.  He added that the situation is even more complicated because even at the “seed stage,”different VCs require different terms.

In fact, he recommended, “Ninety per cent of startups should be bootstrapped (funded by self, friends and family) because other investors expect that they will get their money out within a few years. “With VC funding, you’re becoming a fiduciary…taking on ‘credit card debt’ that you will need to pay back.”

In Beisel’s view, before taking any money from VCs, an entrepreneur needs to know how outsiders view the firm, the reputation of the VC firm, which partner will be best for the company, and whether the firm usually adds to series funding or “will you be one of the 98% that get dropped?”

Health care vs. other  investment
Citing a decline in financing for health care ventures in Massachusetts compared with increased financing for Internet and mobile technology, Hron asked if investors are seeking short-term gains as instead of  taking the long view required for biotechnology and pharma payback.

Webb responded that one reason for the slowdown in health care company funding is that the US Food and Drug Administration is taking longer to approve products so the horizons for investors are longer. As a result, investors are shifting toward healthcare technology, “big data” and products that will bring a quicker return.

In Beisel’s view, “Over the last ten years the returns for health care investment have not been that great; health care is now even more challenging. But VCs won’t shift to other spaces; the money just won’t get raised.”

Long -term trends
According to Hron, the data suggest a rise in VC investing in Washington State, Texas, and Illinois. “Are we seeing the rise of a national VC community or is this a blip?” he asked. “And will VC investors look at companies nationwide?”

Tango and Beisel agreed that large investors are looking at companies nationally and internationally–especially in the Internet space.

They also agreed that it’s unlikely that VCs will spring up in Kansas or in “third-tier American cities,” as Beisel; put it.  In Tango’s view, “they will still be centered in Boston, NY and California.”  Beisel pointed out that that VC firms are on the rise in nations like Argentina and Eastern Europe.  According to Webb, “Capital clusters around academic institutions: You won’t see much density elsewhere.”

Crowd sourcing
Regarding the  recent passage of legislation allowing corporate fundraising through crowd sourcing, panelists expressed concerns about possibilities for fraud and entry of organized crime; and also  that unsophisticated investors might not know that seasoned professionals expect to lose money on most  investments—in hopes that a few will have big payoffs.

Asked by Hron if VCs will look askance at companies raising initial funding through crowd sourcing, Beisel said  that it’s fine to get seed money wherever you can but a “real company” will need institutional investors in order to grow large.

In Tango’s view, “Your source of funding depends on what you want to accomplish: Do you just want to get money…or are you looking for series of VC rounds, advice and support?”

 

PANELIST BIOs

David Beisel – David is Co-Founder and Partner of NextView Ventures, a dedicated seed-stage venture capital firm focused on investments in internet startups.  Previously he was an investor at both Venrock and Masthead Venture Partners, where he served on the boards of BlogHer and Gazelle.  Prior to joining Masthead, he co-founded Sombasa Media, an e-mail marketing company which was successfully acquired by About.com and subsequently became a division of Primedia (NYSE: PRM), where he served as Vice President of Marketing.  He is also the founder of the Web Innovators Group, a quarterly entrepreneur-focused event which attracts nearly a thousand attendees.  David blogs atwww.GenuineVC.com.

Jo Tango – Jo is Founder and Partner of Kepha Partners, an early-stage venture capital firm.   Previously, Jo spent was a General Partner at Highland Capital Partners, where he worked for nearly nine year, and before that he spent five years with Bain & Company.  Jo has invested in the e-commerce, search engine, Internet ad network, wireless, supply chain software, storage, database, security, on-line payments and data center virtualization spaces.  He has been a founding or first institutional investor in Azuki Systems, Bit9, ExaGrid, StreamBase Systems, Vertica Systems (acquired by Hewlett-Packard), Virtual Iron (acquired by Oracle) and VoltDB, getting involved nearly always at the company inception phase. Other investments include Ask Jeeves (Nasdaq: ASKJ), Digital Market (acquired by Agile Software), and NextCard (Nasdaq: NXCD).

C.A. Webb – C.A. became the Executive Director of the New England Venture Capital Association in January 2012.  Members of the NEVCA include more than 700 venture capital professionals from over 100 firms that collectively manage more than $50 billion in capital.  C.A. has spent her career in entrepreneurial roles with mission driven, early stage and high growth organizations. Her work has focused on breakthrough business models in a diverse array of industries including retail and packaged goods (Whole Foods Market), consumer internet technology (Care.com), sustainability (Preserve Products), historic preservation (Trinity Boston Foundation), public education (Boston Collegiate Charter School), and publishing (Fast Company magazine




Health gizmos for non-geeks: new monitoring devices for staying well

You don’t need to be a geek to get into some of the newest technology for keeping track of your health. I was blown away when I heard about pill bottle caps that will tell  you (or your doctor or your caretakers)  if you’ve forgotten to take your meds…a kazoo that measures the chemistry of the air from your lungs…and a telephone that can assess whether you’re depressed–from the tones of your voice.

These gizmos are the brainchildren of David Rose, an entrepreneur who is now the CEO of Vitality, Inc., in Cambridge.  Rose has also invented bathroom scales that can show whether you’ve lost or gained weight, an umbrella that can sense whether it’s going to rain, and objects that assess air quality.

Rose was one of four panelists who spoke last week at a program sponsored by the Medical Development Group about some astounding new health gadgets, most of which are actually on the market. (MDG is a Boston area organization for individuals involved in the medical device and technology industries). 

Rose focused on the above-mentioned pill bottle “Glo-Caps”, which “sense”  when a patient takes a medication, and, via a wireless Internet connection, show health care professionals, patients or caregivers whether reminders are needed.  

The caps light up, play a melody, and even ring a home phone to remind patients to take their pills.  The caps can send weekly emails to remote caregivers, create accountability with doctors through an adherence report, and automatically refill prescriptions. 

Glo-Caps are not currently available for purchase by individuals, but they are being used by patients enrolled in programs sponsored by certain health insurers and pharmacies.

Panelist Ben Rubin, Co-Founder and Chief Technology officer of Zeo, in Newton, MA, described Zeo’s novel  headset and device that monitor an individual’s REM sleep and factors influencing sleep patterns.  Knowing how well you sleep is important because sleep is closely tied to health conditions like obesity, depression, diabetes and the like, Rubin said. “If you measure it, you can manage it.” 

Zeo’s sleep devices, which cost $250,  connect to  an Internet site. For an additional $100, Zeo provides email advice coaching to help individuals improve their “sleep hygiene.” 

There’s also a  Smart Phone application designed to promote better sleep:  using the Ap, you put your phone under your pillow to measure your movement (and restlessness) during sleep.

Panelists also described glucose monitors that send data to doctors via patients’ Smart Phones and Nike running shoes that measure your steps. At one point, Rose pulled out a keychain that tells him whether he’s met his daily walking goals and whether he’s on track (ha ha) to meet his monthly goals.

Also mentioned  were Internet tools such as a Google Ap to measure flu trends; Healthmedia, through which Johnson & Johnson provides digital coaching for managing stress and chronic disease, Philips Direct, which provides live coaching over email, and various “calorie and other body monitors through which individuals can receive online coaching through gyms.

All of these devices fall under a category moderator David Barash, MD, CEO of Concord [MA] Health Strategies calls “local health monitoring” –meaning that the devices can be used by patients or consumers almost anywhere–rather than just at home or in a hospital,  doctor’s office or lab.

 According to a recent review by my client, Scientia Advisors, “remote health monitoring” devices are the fastest growing category in a booming home health care market. 

The devices are growing in popularity in sync with an aging population, increasing chronic disease, and new Internet technologies, Barash said.

Panelist Frank McGillin, Vice President of Global Marketing for Philips Healthcare, which markets a variety of home monitoring devices, said  remote monitoring  will become increasing important in light of growing health care costs.

Gillin cited government statistics showing that  health care current accounts for 17.6 percent of the  gross domestic product in the US, and that by 2050, half of the population in the developed world will be chronically ill—making traditional medical care  fiscally overwhelming. 

Devorah Klein, PhD, a principal at Continuum, in Newton, MA, who designs devices and evaluates patient adherence to therapy regimes for diabetes, asthma, arthritis, multiple sclerosis and erectile dysfunction, emphasized that  simple designs are key because “many patients are not all that interested” in learning to use devices.

And Barash pointed out that while many consumers may be intrigued by these gizmos, doctors have been slow to embrace them.

 For one thing, with a dearth of clinical trials to assess devices’ effectiveness, insurers are reluctant to reimburse doctors for evaluating the data thus compiled.

For another,  it’s not clear how doctors can manage or assess  potentially large amounts of additional data, or  how data collected for individual conditions can be assessed in relation to data collected elsewhere for other, possibly related, conditions.

–Anita M. Harris

New Cambridge Observer is published by the Harris Communications Group, a  writing  and public relations firm in Cambridge, MA.  All rights reserved.